Virtual Symposium (Expired): Patient-focused LDL-C Management and Risk Reduction in Clinical Practice: The Utility of PCSK9 Inhibitors

During this comprehensive learning experience, expert faculty will examine current lipid guidelines, the unmet need and residual risk of poorly controlled LDL-C, and exciting genetic insights that have expanded treatment targets. Participants will leave with the latest information on novel LDL lowering therapies, including PCSK9 inhibitors. Clinical case examples will provide tactics for treatment intensification and how best to integrate new therapies into management plans for high-risk patients.

LDL-C Lowering Therapies Beyond Statin Therapy

Faculty: Christie M. Ballantyne, MD

A Natural Human Experiment: PCSK9 and Cholesterol

Faculty: Henry N. Ginsberg, MD

PCSK9 Inhibitors in Practice: Efficacy, Safety, Barriers and Benefits

Faculty: Christie M. Ballantyne, MD

Case Discussion and Audience Q&A: Management of Patients with High Residual CVD Risk

Faculty: James A. Underberg, MD

Presenter: All Faculty